HY-153715 Search Results


forskolin  (MedChemExpress)
96
MedChemExpress forskolin
a Schematic of protocols for PKD disease modeling followed by drug testing. b Bright-field image of PKD organoids treated with 30 µM <t>forskolin</t> for 48 h in UniMat. Scale bar = 200 µm. Arrows indicate cyst formation within kidney organoids. c Bright-field images of individual PKD organoids induced from kidney organoids differentiated in hydrogel layer, AggreWell, and UniMat. Scale bars = 200 µm. d Bright-field images of individual PKD organoids treated with CFTR inhibitor-172 for 24 h, induced from kidney organoids differentiated in hydrogel layer, AggreWell, and UniMat. Scale bars = 200 µm. e Percent areas of individual forskolin-treated kidney organoids compared to average area of organoids before treatment from 3 independent batches. ( n = 9 organoids for all conditions in hydrogel layer and UniMat, and n = 14, 9, and 12 organoids for AggreWell at 0, 10, and 30 µM forskolin, respectively, mean ± SD). Significance by one-way ANOVA with Tukey’s multiple comparisons test: P 0 µM, 30 µM = 0.0002, P 10 µM, 30 µM = 0.0236 (UniMat). f Percent areas of CFTR inhibitor-172-treated kidney organoids compared to average area of organoids before treatment from 3 independent batches ( n = 9 organoids for all conditions in hydrogel layer, n = 11, 11, and 14 organoids for AggreWell at 0, 10, and 30 µM forskolin, respectively, and n = 12 organoids for all conditions in UniMat, mean ± SD). Significance by one-way ANOVA with Tukey’s multiple comparisons test: P 0 µM, 10 µM = 0.0002, P 10 µM, 30 µM = 0.0378 (UniMat). Source data are provided as a Source Data file.
Forskolin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/forskolin/product/MedChemExpress
Average 96 stars, based on 1 article reviews
forskolin - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


a Schematic of protocols for PKD disease modeling followed by drug testing. b Bright-field image of PKD organoids treated with 30 µM forskolin for 48 h in UniMat. Scale bar = 200 µm. Arrows indicate cyst formation within kidney organoids. c Bright-field images of individual PKD organoids induced from kidney organoids differentiated in hydrogel layer, AggreWell, and UniMat. Scale bars = 200 µm. d Bright-field images of individual PKD organoids treated with CFTR inhibitor-172 for 24 h, induced from kidney organoids differentiated in hydrogel layer, AggreWell, and UniMat. Scale bars = 200 µm. e Percent areas of individual forskolin-treated kidney organoids compared to average area of organoids before treatment from 3 independent batches. ( n = 9 organoids for all conditions in hydrogel layer and UniMat, and n = 14, 9, and 12 organoids for AggreWell at 0, 10, and 30 µM forskolin, respectively, mean ± SD). Significance by one-way ANOVA with Tukey’s multiple comparisons test: P 0 µM, 30 µM = 0.0002, P 10 µM, 30 µM = 0.0236 (UniMat). f Percent areas of CFTR inhibitor-172-treated kidney organoids compared to average area of organoids before treatment from 3 independent batches ( n = 9 organoids for all conditions in hydrogel layer, n = 11, 11, and 14 organoids for AggreWell at 0, 10, and 30 µM forskolin, respectively, and n = 12 organoids for all conditions in UniMat, mean ± SD). Significance by one-way ANOVA with Tukey’s multiple comparisons test: P 0 µM, 10 µM = 0.0002, P 10 µM, 30 µM = 0.0378 (UniMat). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Scalable production of uniform and mature organoids in a 3D geometrically-engineered permeable membrane

doi: 10.1038/s41467-024-53073-z

Figure Lengend Snippet: a Schematic of protocols for PKD disease modeling followed by drug testing. b Bright-field image of PKD organoids treated with 30 µM forskolin for 48 h in UniMat. Scale bar = 200 µm. Arrows indicate cyst formation within kidney organoids. c Bright-field images of individual PKD organoids induced from kidney organoids differentiated in hydrogel layer, AggreWell, and UniMat. Scale bars = 200 µm. d Bright-field images of individual PKD organoids treated with CFTR inhibitor-172 for 24 h, induced from kidney organoids differentiated in hydrogel layer, AggreWell, and UniMat. Scale bars = 200 µm. e Percent areas of individual forskolin-treated kidney organoids compared to average area of organoids before treatment from 3 independent batches. ( n = 9 organoids for all conditions in hydrogel layer and UniMat, and n = 14, 9, and 12 organoids for AggreWell at 0, 10, and 30 µM forskolin, respectively, mean ± SD). Significance by one-way ANOVA with Tukey’s multiple comparisons test: P 0 µM, 30 µM = 0.0002, P 10 µM, 30 µM = 0.0236 (UniMat). f Percent areas of CFTR inhibitor-172-treated kidney organoids compared to average area of organoids before treatment from 3 independent batches ( n = 9 organoids for all conditions in hydrogel layer, n = 11, 11, and 14 organoids for AggreWell at 0, 10, and 30 µM forskolin, respectively, and n = 12 organoids for all conditions in UniMat, mean ± SD). Significance by one-way ANOVA with Tukey’s multiple comparisons test: P 0 µM, 10 µM = 0.0002, P 10 µM, 30 µM = 0.0378 (UniMat). Source data are provided as a Source Data file.

Article Snippet: Subsequently, they were exposed to forskolin (10 and 30 μM) for 48 h. Inhibition of cytogenesis was achieved by treating CFTR inhibitor-172 (HY-16671, MedChemExpress).

Techniques: